Celltrion Inc - Company Profile
Powered by 
All the sales intelligence you need on Celltrion Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Celltrion Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Celltrion Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis, and psoriasis. Its pipeline portfolio spans monoclonal antibody biosimilars for the treatment of rheumatoid arthritis; colorectal cancer; and respiratory disease; and antibody biologics and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, and seasonal influenza. Celltrion develops drugs by using its bioengineering and mammalian cell-culture technology. It also carries out contract manufacturing of biosimilars. The company has an operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon, South Korea
Headquarters
South Korea
Address
23, Academy-Ro, Yeonsu-Gu, Incheon, Gangwon, 22014
Website
www.celltrion.com
Telephone
82 328 505000
No of Employees
1,074
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
068270 (KRX)
Revenue (2024)
$2.9B
17%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
143.6%
(2024 vs 2023)
Market Cap*
$26.4B
Net Profit Margin (2024)
XYZ
108.3%
(2024 vs 2023)
* As of and is in US$
Celltrion Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Marketed Drugs: | Non-GMP Biomanufacturing Service | Actos |
| Biosimilars | cGMP Biomanufacturing Service | Albothyl |
| Novel Therapeutics | Project Management | Avtozma |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In June, the company launched its cancer biosimilars Truxima (rituximab) and Vegzelma (bevacizumab) in Vietnam. |
| 2026 | New Products/Services | In May, the company launched artificial intelligence into three business areas: new drug development, manufacturing, and administration. |
| 2026 | Acquisitions/Mergers/Takeovers | In May, the company acquired Gifrer, a health care company. |
Competitor Comparison
| Key Parameters | Celltrion Inc | Amgen Inc | Sandoz Group AG | Biocon Biologics Ltd | Samsung Bioepis Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | United States of America | Switzerland | India | South Korea |
| City | Incheon | Thousand Oaks | Basel | Bengaluru | Incheon |
| State/Province | Gangwon | California | Basel-Stadt | Karnataka | Seoul |
| No. of Employees | 1,074 | 31,500 | 23,567 | 5,824 | 1,000 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jinseok Seo | Chief Executive Officer; Chairman | Executive Board | 2024 | 42 |
| Woosung Kee | Chief Executive Officer; Director | Executive Board | 2023 | 65 |
| Mincheol Shin | Director; Chief Financial Officer | Executive Board | 2023 | 55 |
| Jungjin Seo | Chairman | Executive Board | 2025 | 69 |
| Choi Byeong-seo | Director; Head-Global Marketing Division | Executive Board | - | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer